The pathophysiology of multiple sclerosis: the mechanisms underlying the production of symptoms and the natural history of the disease

被引:225
作者
Smith, KJ
McDonald, WI
机构
[1] Kings Coll London, Guys Kings & St Thomas Sch Med, Dept Clin Neurosci, London SE1 9RT, England
[2] Royal Coll Physicians, London NW1 4LE, England
关键词
demyelination; pathophysiology; conduction block; inflammation; ectopic impulses; axonal degeneration;
D O I
10.1098/rstb.1999.0510
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
The pathophysiology of multiple sclerosis is reviewed, with emphasis on the axonal conduction properties underlying the production of symptoms, and the course of the disease. The major cause of the negative symptoms during relapses (e.g. paralysis, blindness and numbness) is conduction block, caused largely by demyelination and inflammation, and possibly by defects in synaptic transmission and putative circulating blocking factors. Recovery from symptoms during remissions is due mainly to the restoration of axonal function, either by remyelination, the resolution of inflammation, or the restoration of conduction to axons which persist in the demyelinated state. Conduction in the latter axons shows a number of deficits, particularly with regard to the conduction of trains of impulses and these contribute to weakness and sensory problems. The mechanisms underlying the sensitivity of symptoms to changes in body temperature (Uhthoff's phenomenon) are discussed. The origin of 'positive' symptoms, such as tingling sensations, are described, including the generation of ectopic trains and bursts of impulses, ephaptic interactions between axons and/or neurons, the triggering of additional, spurious impulses by the transmission of normal impulses, the mechanosensitivity of axons underlying movement-induced sensations (e.g. Lhermitte's phenomenon) and pain. The clinical course of the disease is discussed, together with its relationship to the evolution of lesions as revealed by magnetic resonance imaging and spectroscopy. The earliest detectable event in the development of most new lesions is a breakdown of the blood-brain barrier in association with inflammation. Inflammation resolves after approximately one month, at which time there is an improvement in the symptoms. Demyelination occurs during the inflammatory phase of the lesion. An important mechanism determining persistent neurological deficit is axonal degeneration, although persistent conduction block arising from the failure of repair mechanisms probably also contributes.
引用
收藏
页码:1649 / 1673
页数:25
相关论文
共 267 条
[1]   FACIAL MYOKYMIA IN MULTIPLE SCLEROSIS [J].
ANDERMANN, F ;
LLOYDSMITH, DL ;
GLOOR, P ;
MCNAUGHTON, FL ;
COSGROVE, JB .
BRAIN, 1961, 84 (01) :31-&
[2]   SUDDEN-DEATH IN MULTIPLE-SCLEROSIS ASSOCIATED WITH SUN EXPOSURE - A REPORT OF 2 CASES [J].
AVIS, SP ;
PRYSEPHILLIPS, WEM .
CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, 1995, 22 (04) :305-307
[3]   Activation of the inducible form of nitric oxide synthase in the brains of patients with multiple sclerosis [J].
Bagasra, O ;
Michaels, FH ;
Zheng, YM ;
Bobroski, LE ;
Spitsin, SV ;
Fu, ZF ;
Tawadros, R ;
Koprowski, H .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (26) :12041-12045
[4]   ECTOPIC ACTIVITY IN DEMYELINATED SPINAL ROOT AXONS OF THE RAT [J].
BAKER, M ;
BOSTOCK, H .
JOURNAL OF PHYSIOLOGY-LONDON, 1992, 451 :539-552
[5]   THE LONGSTANDING MS LESION - A QUANTITATIVE MRI AND ELECTRON-MICROSCOPIC STUDY [J].
BARNES, D ;
MUNRO, PMG ;
YOUL, BD ;
PRINEAS, JW ;
MCDONALD, WI .
BRAIN, 1991, 114 :1271-1280
[6]   INTERLEUKIN-1-BETA INHIBITS SYNAPTIC STRENGTH AND LONG-TERM POTENTIATION IN THE RAT CA1 HIPPOCAMPUS [J].
BELLINGER, FP ;
MADAMBA, S ;
SIGGINS, GR .
BRAIN RESEARCH, 1993, 628 (1-2) :227-234
[7]   NEUROLOGICAL DEFICITS FOLLOWING THE HOT BATH TEST IN MULTIPLE-SCLEROSIS - REPLY [J].
BERGER, JR ;
SHEREMATA, WA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1985, 253 (02) :203-203
[8]   PERSISTENT NEUROLOGICAL DEFICIT PRECIPITATED BY HOT BATH TEST IN MULTIPLE-SCLEROSIS [J].
BERGER, JR ;
SHEREMATA, WA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1983, 249 (13) :1751-1753
[9]   THE EFFECTS OF 4-AMINOPYRIDINE IN MULTIPLE-SCLEROSIS PATIENTS - RESULTS OF A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, CONCENTRATION-CONTROLLED, CROSSOVER TRIAL [J].
BEVER, CT ;
YOUNG, D ;
ANDERSON, PA ;
KRUMHOLZ, A ;
CONWAY, K ;
LESLIE, J ;
EDDINGTON, N ;
PLAISANCE, KI ;
PANITCH, HS ;
DHIBJALBUT, S ;
FOSSLER, MJ ;
DEVANE, J ;
JOHNSON, KP .
NEUROLOGY, 1994, 44 (06) :1054-1059
[10]   THE CURRENT STATUS OF STUDIES OF AMINOPYRIDINES IN PATIENTS WITH MULTIPLE-SCLEROSIS [J].
BEVER, CT .
ANNALS OF NEUROLOGY, 1994, 36 :S118-S121